Literature DB >> 16568888

Plasmid vaccines and therapeutics: from design to applications.

Marston Manthorpe1, Peter Hobart, Gary Hermanson, Marilyn Ferrari, Andrew Geall, Blake Goff, Alain Rolland.   

Abstract

In the late 1980s, Vical and collaborators discovered that the injection into tissues of unformulated plasmid encoding various proteins resulted in the uptake of the plasmid by cells and expression of the encoded proteins. After this discovery, a period of technological improvements in plasmid delivery and expression and in pharmaceutical and manufacturing development was quickly followed by a plethora of human clinical trials testing the ability of injected plasmid to provide therapeutic benefits. In this chapter, we summarize in detail the technologies used in the most recent company-sponsored clinical trials and discuss the potential for future improvements in plasmid design, manufacturing, delivery, formulation and administration. A generic path for the clinical development of plasmid-based products is outlined and then exemplified using a case study on the development of a plasmid vaccine from concept to clinical trial.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16568888     DOI: 10.1007/10_003

Source DB:  PubMed          Journal:  Adv Biochem Eng Biotechnol        ISSN: 0724-6145            Impact factor:   2.635


  2 in total

1.  A TaqMan reverse transcription polymerase chain reaction (RT-PCR) in vitro potency assay for plasmid-based vaccine products.

Authors:  Rohit Mahajan; Beth Feher; Basil Jones; Doug Jones; Lana Marjerison; Mindy Sam; Jukka Hartikka; Mary Wloch; Peggy Lalor; David Kaslow; Keith Hall; Alain Rolland
Journal:  Mol Biotechnol       Date:  2008-03-26       Impact factor: 2.695

Review 2.  DNA vaccines for targeting bacterial infections.

Authors:  Mariana Ingolotti; Omkar Kawalekar; Devon J Shedlock; Karuppiah Muthumani; David B Weiner
Journal:  Expert Rev Vaccines       Date:  2010-07       Impact factor: 5.217

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.